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Abstract: Gambiense human African trypanosomiasis
(HAT, sleeping sickness) is widely assumed to be 100%
pathogenic and fatal. However, reports to the contrary
exist, and human trypano-tolerance has been postulated.
Furthermore, there is uncertainty about the actual
duration of both stage 1 and stage 2 infection, particularly
with respect to how long a patient remains infectious.
Understanding such basic parameters of HAT infection is
essential for optimising control strategies based on case
detection. We considered the potential existence and
relevance of human trypano-tolerance, and explored the
duration of infectiousness, through a review of published
evidence on the natural progression of gambiense HAT in
the absence of treatment, and biological considerations.
Published reports indicate that most gambiense HAT
cases are fatal if untreated. Self-resolving and asymptom-
atic chronic infections probably constitute a minority if
they do indeed exist. Chronic carriage, however, deserves
further study, as it could seed renewed epidemics after
control programmes cease.
Introduction
Human African trypanosomiasis (HAT, sleeping sickness) due to
Trypanosoma brucei gambiense is a disease of long duration. However,
our understanding of the natural progression of gambiense HAT
infection in the absence of treatment remains surprisingly poor.
Parasites become patent in the blood within 1–2 weeks of
infection, heralding the haemolymphatic stage (stage 1), which is
characterised by non-specific signs and symptoms. Eventually,
parasites penetrate the blood–brain barrier (BBB), leading to the
meningoencephalitic stage (stage 2), which features more specific
signs and neurological symptoms, and leads to coma and death.
A commonly held assumption is that HAT always [1] or almost
always [2,3,4] progresses to stage 2, and is always fatal if untreated
[4,5]. However, the empirical evidence to support this assumption
is limited, and, at least theoretically, four ‘‘trypano-tolerant’’
alternative outcomes are possible: (i) early (i.e., within weeks or
months) spontaneous resolution of stage 1; (ii) chronic, asymp-
tomatic, or mildly symptomatic carriage in stage 1 without
progressing to stage 2; (iii) progression to stage 2 followed by early
spontaneous resolution; and (iv) chronic, asymptomatic, or mildly
symptomatic carriage in stage 2 (Figure 1).
There is uncertainty about the average duration of stage 1 and
stage 2 pathogenic gambiense infections in the absence of
treatment, and its degree of variation across cases. Stage 1 has
been reported to last ‘‘many months, sometimes over two years’’
[6] or ‘‘several months to two years’’ [5]. The duration of its
asymptomatic phase may be many months if not years [2,5], and
this is followed by ‘‘a few months’’ of a non-specific syndrome [7].
Sir Patrick Manson wrote that disease may start as late as 7 years
after HAT infection [4]. After the onset of stage 2, death occurs
‘‘within a few months, but may be delayed for up to a year’’ [6],
‘‘from four months to one year’’ [5], or from ‘‘four to eight
months, exceptionally beyond one year’’, according to Manson
[4]. There is probably a systematic delay in the detection of stage
2, since parasites may take some time to travel from the brain to
the lumbar region, where punctures to collect cerebrospinal fluid
(CSF) for diagnostic purposes are usually taken for reasons of
safety. The extent of this delay is not known. Overall, the entire
duration of the infection may be ‘‘from one to three years after
onset’’ of initial symptoms [8], or ‘‘2–5 years’’ [9].
Gambiense HAT control is largely based on case detection
and treatment. This reduces the duration of infectiousness and
thus diminishes onward transmission and the effective repro-
ductive ratio (the average number of secondary cases arising
from one case). While active case detection through mass
screening campaigns is associated with substantial reductions in
HAT transmission, total elimination (defined here as zero
transmission) has proved hard to achieve. For example, historical
foci in Cameroon [10] and the Ivory Coast [11] have survived at
low prevalence despite years of case detection. Numerous
hypotheses have been advanced to explain this extraordinary
persistence. These include constant reseeding with infections
from outside the focus; the role of a putative animal reservoir;
and the existence of chronic, asymptomatic carriers, or cases of
extremely long infection, which maintain low-level transmission
and, once control is relaxed, may lead to a new outbreak.
Indeed, the epidemiological dynamics of a pool of undetected
chronic carriers would be similar to that of an animal reservoir,
already shown theoretically to reduce the transmission impact of
case detection [12].
Clearly, the latter hypothesis can only be addressed if one
tackles fundamental unknowns. For example, do some HAT
infections progress to non-pathogenic outcomes, and if so, with
what frequency? What is the range of duration of untreated
infections? The potential impact of interventions to reduce HAT
transmission through prompt case detection is greater the longer
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if asymptomatic (or benignly symptomatic) chronic carriers do
make up a significant proportion of infected people, control
strategies based on passive case detection of ill patients might
never be sufficient to eliminate HAT, and active case detection,
with treatment irrespective of symptoms, would be required to
interrupt transmission. On the other hand, exposing asymptomatic
cases who will not progress to disease to the toxic and cumbersome
HAT drugs currently available would entail an unnecessary risk of
side effects.
Better evidence on the above issues would be directly useful for
clinicians and HAT control programmes. Moreover, the long-term
strategy to control and possibly eliminate HAT would benefit from
quantitative predictions of the impact on transmission and
mortality of different HAT control strategies, and of the duration
and intensity of control needed to achieve set targets. Mathemat-
ical models can produce such predictions and have guided policy
decisions for various tropical diseases, including onchocerciasis
[13] and schistosomiasis [14]. However, these models are
misleading if they are based on inaccurate assumptions about
the basic parameters of the infection in hosts and vectors. The
present paper aims to improve current evidence on some of the
key human parameters, with a view to developing more realistic
and thus useful models of HAT transmission.
We recently derived an indirect estimate of the duration of
untreated pathogenic stages 1 and 2 HAT [15]. Here, we present a
literature review of the duration and evolution of T .b. gambiense
infections in the absence of treatment, and biological consider-
ations about the parasite. Throughout this paper, ‘‘HAT’’ refers to
gambiense infection.
Literature Review
Search Strategy and Results
A PubMed MeSH search of Medline references under the
general term ‘‘Trypanosomiasis, African’’, covering the period
1953–2006, was performed. We also did simple PubMed searches
with all possible combinations of the terms ‘‘healthy carrier’’,
‘‘disease progression’’, ‘‘duration’’, ‘‘latency’’, ‘‘tolerant’’, or
‘‘tolerance’’ with the terms ‘‘sleeping sickness’’, ‘‘trypanosome’’,
‘‘trypanosomiasis’’, or ‘‘trypanosomosis’’, as well as the French,
Spanish, Portuguese, and German terms for ‘‘trypanosomiasis’’
and ‘‘sleeping sickness’’. We screened resulting references for
articles concerned with in vivo human infections, excluding
general clinical reviews. We also screened all African trypanoso-
miasis abstracts contained in the Tropical Disease Bulletin (a
comprehensive abstract book for tropical medicine, covering
journals published in English, French, Spanish, Portuguese,
German, and Italian) from 1910 until 1952. We followed the
bibliographic trail of each relevant citation backwards in time until
its exhaustion. We also reviewed all meeting reports of the
International Scientific Committee for Trypanosomiasis Research,
and contacted ten leading HAT experts. We generally limited our
search to reports published since 1910; before that time, HAT
parasitology and diagnosis, as well as scientific journals, were in
their infancy.
We focussed on three types of report. First, we identified reports
of the natural progression of infection in untreated patients whose
status at baseline and at the end of observation was known, and we
only retained those in which patients’ diagnosis was confirmed
microscopically or by the polymerase chain reaction (PCR).
Second, we identified reports of the duration of stage 1, stage 2, or
both in untreated patients who did progress to disease or death,
and here we included patients irrespective of whether diagnosis
had been confirmed parasitologically. Third, we identified reports
of infections confirmed by microscopy or PCR at baseline that had
cleared (at least three consecutive negative blood samples) without
treatment at the end of the observation period.
The search yielded 27 eligible reports of the natural progression
of gambiense infection, 42 eligible reports of the duration of
infections progressing to disease, and four reports of spontaneously
cleared infections. We also found three reviews [16,17,18]. One
reference could not be retrieved [19].
General Quality of Reports
Most reports contained little detail on study methods, and few
relied on substantial sample sizes (Table 1 and Table 2). Only
some studies began observing patients at the time of infection and/
or followed them until death or cure. Most reports listed patient
status at baseline or end of follow-up simply as ‘‘stage 1’’ or ‘‘stage
2’’, without information about time elapsed since infection or stage
2 progression. Some studies included a mix of stage 1 and 2
patients.
Furthermore, potential sources of bias that specifically weaken
the strength of inference were ubiquitous (Table 3), and no studies
was unaffected by at least one of these biases. A large proportion of
studies were conducted during the years when microscopic
inspection of lymph node aspirates, blood, or CSF was the sole
means of diagnosis, and the taxonomy of trypanosomes was not
well established. It is now known that light microscopy is a very
insensitive technique [20], mainly due to the low and undulating
parasitaemia characteristic of HAT. More importantly, several
non-pathogenic trypanosome species, such as T. congolense, T. brucei
brucei (bouafle ´), and T. evansi, are now known to occasionally infect
humans [21,22,23,24], yet these forms are essentially indistin-
guishable from T. b. gambiense by microscopy. Positive microscopy
in the presence of symptoms typical of HAT would have reduced
the likelihood of such species misdiagnosis, but not entirely, since
Figure 1. Possible Outcomes of Untreated Gambiense Human African Trypanosomiasis.
doi:10.1371/journal.pntd.0000303.g001
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www.plosntds.org 5 December 2008 | Volume 2 | Issue 12 | e303several diseases, such as malaria, tuberculosis, and HIV, can
mimic HAT. Whilst recognising these shortcomings, it is
important to note that such occurrences are rare.
Publication bias is also possible; for example, studies showing
unusual outcomes could have been reported more frequently than
those confirming the textbook pattern, and may thus make up a
disproportionate fraction of the literature in our review, potentially
suggesting that some phenomena are more frequent than they
actually are.
Reports of the Natural Progression of HAT
Quantifying the relative frequency of different outcomes of
untreated infection would allow for the development of realistic
mathematical models that (i) predict the proportion of infections
that will not become symptomatic and thus will not be captured by
passive case detection, (ii) explore the contribution of these non-
pathogenic infections to maintaining transmission, (iii) help to
optimise screening strategies that target non-pathogenic infections
with the ultimate aim of eliminating foci altogether, and (iv)
predict the impact of different control strategies on morbidity and
mortality.
Eligible reports of the outcome of untreated HAT (Table 1) are
hard to interpret, mainly because the observation periods are
censored at about 3 years for the largest case series, and because
the case series are a mix of early and late infections. As expected,
the case fatality ratio generally increased when the duration of
observation was longer, reaching 73% in a case series in the
Belgian Congo that was followed for 4 and a half years [25]. Case
fatality ratios were calculated based on cases known to have died,
but would be higher if patients who disappeared or had an
unknown endpoint are considered dead, notably for the series by
Marshall and Vassallo [26] and Heckenroth [27]; indeed, in the
latter study only three of 36 patients (8.3%) were known to remain
healthy after 4 years of follow-up.
Two reports contradict this general trend in case fatality. In
Ivory Coast, Jamonneau et al. [28,29] observed a group of 15
parasitologically confirmed patients who refused treatment. After 4
years, at least seven were no longer parasitaemic, only one
progressed to stage 2, and of the remainder, only three had clinical
signs of stage 1. Six of the patients were followed for a further 2-
year period, at the end of which three were mildly ill, and all were
parasite-negative microscopically but PCR-positive. Genotyping
using microsatellite markers revealed that two were mono-infected
with a new T. brucei s.l. strain, while four had a co-infection with
the new strain and T. b. gambiense group 1. In The Gambia, Todd
[30,31] traced 12 patients over 9 years following initial diagnosis,
and found eight still healthy, of whom one was seen again 13 years
later and found to be clinically well despite reportedly not
receiving treatment.
This review does not include the famous ‘‘FEO’’ case, a
Togolese female who remained parasitaemic and healthy over 23
years of follow-up, despite repeated treatment courses [32]; the
strain was morphologically consistent with T. b. gambiense, but
induced more chronic infections in animals, and may have been
non-gambiense.
Reports of Spontaneous Infection Clearance
Reports of spontaneous infection clearance are rare. Harding
and Hutchinson [33] report that nine out of 75 Sierra Leonean
asymptomatic parasite-positive cases at baseline no longer showed
parasites in weekly tests over the next 2 months. In this community
(Fuero), no significant mortality attributable to HAT was noted in
spite of infection attack rates .25% over 3 years. Presenting cases
were asymptomatic, with infrequent cervical gland involvement
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www.plosntds.org 6 December 2008 | Volume 2 | Issue 12 | e303and scanty parasitaemia. Interestingly, case finding and mass
chemoprophylaxis were less successful in controlling transmission
in this site than in neighbouring areas where classical HAT was
prevalent. The authors speculated that a novel strain could have
been responsible for the atypical outbreak in Fuero.
Dyleff [34] reported that three Europeans returning from the
French Congo, who were positive for HAT at an initial test,
subsequently tested negative in all further tests in various
laboratories.
Barlovatz [35] described a patient from the Belgian Congo who
refused treatment. Three years and 3 months later, various tests,
including inoculation of six Guinea pigs with his blood, were
negative.
Cooke et al. [36] reported on an Englishman returning from
Nigeria and Ghana who, upon post-repatriation screening, was
found to be infected but mistakenly discharged without treatment;
6 months later no trypanosomes were found in blood films or upon
animal inoculation. The patient was nonetheless treated as a
precaution.
Reports of the Duration of HAT Infections Progressing to
Disease
The duration of pathogenic HAT infections is a critical
parameter for the development of predictive mathematical models
since it determines opportunities for further transmission to flies
and for case detection before the onset of irreversible sequelae or
death. The rates of progression from stage 1 to stage 2 from stage 2
to death are also indispensable parameters in any model of HAT
transmission.
Most reports on the progression of HAT have been based on
individuals developing HAT disease after exposure to tsetse bites
at a known point in time. While baseline and endpoint status
differs widely across these studies, the duration of T. b. gambiense
stage 1 ranged from a few months to a few years (Table 2). Only
three cases with duration beyond 8 years were found among these
reports (including a patient who took at least 12 years to progress
from infection to stage 2, and another for whom at least 15 years
elapsed between stage 1 and 2). An unknown number of cases of
advanced stage 2 were diagnosed clinically by Gue ´rin in the
Caribbean among slaves abducted from West Africa 5–8 years
earlier [4]. Four of the larger series suffered from considerable
selection bias: Blum et al. [37], Blum et al. [38], Edan [39], and
Milord et al. [40] studied stage 2 patients coming for treatment
whose duration of symptoms was probably dependent on
treatment-seeking behaviour; Greggio [25] only included patients
who had already died by the time of the study, thus biasing
observations towards short duration cases. Nonetheless, all large
series showed a left-skewed distribution of duration (unpublished
data), with fewer than 5% of cases lasting more than 4 years up to
a maximum of 6 to 7 years. Interestingly, Manson believed that
HAT symptoms can arise up to seven years post infection [4].
Residents of Gore ´e Island (Senegal) also reportedly considered
themselves safe from HAT if no symptoms arose in the 7 years
after a trip to the mainland [4]. Fe `vre et al. [18] aggregated 88
patients reviewed in Yorke [17] and 8 patients reported after
diagnosis in Europe and North America (all presented here with
the original citations), all of whom had a plausible time of infection
and known time of death or treatment; survival analysis suggested
a median duration of infection of 36 months. Checchi et al. [15]
derived indirect estimates of stage 1 duration (mean 17 months,
median 12 months) from survival analysis of 298 untreated
serological suspects’ time to progression from suspected stage 1 to
confirmed stage 2, and deduced stage 2 duration (mean 16
months, median 11 months) from the observed stage 1 to 2 ratio in
the community. This gives a rough estimate of 33 months for the
mean total duration of infection. Subsequent adjustment for
diagnostic specificity and stage misclassification, however, suggests
that the mean stage 2 duration may have been overestimated, and
could be closer to 10 months (Checchi et al., unpublished
observations).
Biological Considerations
Natural Progression
The assumed 100% lethality of HAT seems surprising from an
evolutionary perspective: over time, parasites are believed to
regulate their virulence so as to avoid killing off their primary
hosts, which for gambiense HAT are humans (an animal reservoir
has been demonstrated [41], but is generally considered of
marginal importance [42]). Furthermore, where HAT has been a
major cause of mortality, evolutionary pressure on humans might
have resulted in the development of trypano-tolerance. Among
infectious agents that rely heavily on humans as a reservoir, none is
known to be 100% fatal, with the possible exception of HIV,
which is a relatively new disease in humans, and for which non-
disease progressors are already reported [43]. This classical
paradigm of evolutionary drift towards non-virulence has been
challenged, especially for vector-borne and other indirectly
transmitted pathogens, which tend to be more virulent than
directly transmitted pathogens, and may require high virulence to
debilitate hosts, potentially exposing them to greater transmission,
for example through more intense vector bites [44]. However,
HAT does not fit this pattern: HAT patients’ prostration actually
reduces their contact with tsetse colonies around watering points
or cultivation areas. Furthermore, much mortality from infections
is in fact caused by host immunopathology, which may not be an
intended outcome for the parasite [45]. HAT may fit this scenario:
death occurs as a result of inflammatory processes, rather than
damage from parasite exploitation of the host’s tissues.
T. b. gambiense survives the haemolymphatic immune response
through an underlying resistance to lytic factors in human serum,
including apolipoprotein L1 (non-human infectious trypanosome
species do not have this ability) [46]. They also resist the acquired
immune response through a process of surface antigenic variation
whereby new antigenic sub-populations constantly arise, thus
escaping antibody-mediated immunity [47]. The repertoire of
variant surface glycoprotein (VSG) genes runs into the order of a
thousand, and the potential repertoire grows as genetic recombi-
nation ensures the genes mutate and evolve even within the course
of an infection. One could speculate that any HAT infection
would eventually disappear when this repertoire is exhausted, as is
the case for Borrelia spp., the causative agent of relapsing fever.
However, current uncertainty about rates of VSG switching,
which range from .1 per 10
3 to ,1 per 10
6 parasite replications
[48], makes it difficult to predict when an infection might deplete
its repertoire of antigens and therefore how long any chronic
carriage might last relative to the host’s lifespan. To our
knowledge, no other extracellular microparasitic infections based
in the haemolymphatic system are known to survive long periods
in the human host without colonising specific tissues. The
existence of intracellular forms of T. brucei has been proposed:
this suggestion rests on weak evidence, but has not formally been
disproved [49].
How else could spontaneous parasite clearance occur? When
specific immunity to the currently expressed VSG is at its peak,
parasite density hits a trough, before recovering as a new VSG
population emerges. Even at its lowest level, total parasite numbers
probably remain in the thousands (assuming a minimum
www.plosntds.org 7 December 2008 | Volume 2 | Issue 12 | e303parasitaemia of 10/mL and 5 L of blood), and it is therefore
unlikely that the infection would be extinguished due to chance.
Some strains, however, might feature an abnormally slow VSG
switching rate, allowing host immunity to eradicate the current
antigenic sub-population before the next one takes over.
Alternatively, certain strains might not express genes coding for
resistance to human serum. Unlike in T. b. rhodesiense, serum
resistance is believed to be a stable trait in T. b. gambiense, but
exceptions might occur. However, one might expect such strains to
go extinct due to selection pressure, and therefore to not feature
prominently among those circulating at any given time.
An alternative hypothesis is that some humans carry trypano-
tolerance traits, as noted already in various animal species in
whom trypanosomes do not necessarily lead to death [50,51]. It is
also possible that certain human sub-populations might be
deficient in genes encoding lytic factors for non-gambiense
trypanosomes (such as T. congolense or T. brucei brucei), which might
survive briefly in the blood, cause only mild illness, and be
mistaken for gambiense. Indeed, a recently reported case of T.
evansi infecting a man in India involved a patient deficient in
apolipoprotein L1 [52].
Chronic carriage, on the other hand, would presumably occur if
the host cannot overcome the haemolymphatic infection, but the
parasites do not cross the BBB. T. b. gambiense itself may modify the
permeability of the BBB, either directly through signalling and
endothelial cell apoptotic pathways, or indirectly due to immuno-
pathogenic effects of infection in the haemolymphatic system [53].
Parasites initially invade the central nervous system (CNS) through
vulnerable points such as the choroid plexus and the thalamus.
CNS invasion may carry mixed evolutionary advantages for the
parasite, as it allows escape from host immunity, but also leads to
earlier host death and thus shorter duration of infectiousness.
Possible mechanisms for chronic carriage include (i) failure of
given strains to modify BBB permeability, for example because
they do not express certain factors (e.g., proteases believed to be
required for BBB entry [54]); (ii) strains reproducing at such a slow
rate that the parasite density remains extremely low, such that any
CNS invasion is limited or benign; and (iii) humans with
trypanosome-impermeable BBB. To our knowledge, empirical
evidence supporting any of these models has yet to be obtained.
Variability in Duration of Infectiousness
The time over which patients remain infectious, at least in
pathogenic cases, is determined by how fast stages 1 and 2
progress. Variability in these parameters could be influenced by a
number of parameters, including differences in strain virulence,
host immunity, and host BBB permeability.
What is the typical rate of progression from stage 1 to stage 2 in
pathogenic infections that do cross the BBB? Assuming that BBB
modification due to HAT infection within any individual is a
continuous process, and given that parasite density in the
haemolymphatic system is known to undulate around a roughly
constant average, the risk of CNS penetration per unit time, i.e.,
progression from stage 1 to stage 2, should be constant, and
proportional to parasite density (obviously, differences in virulence
across strains will create variability in this risk among individual
infections). A constant risk of stage 2 progression would result in a
negative exponential distribution of the duration of stage 1 (see
Figure 2 for an illustration). Such a distribution would feature a
relatively short median duration, but also comprise a tail of very
long durations—in other words, ‘‘exceptions’’ would be expected.
Indeed, this exponential decay hypothesis is corroborated by
survival analysis of untreated serological suspects [15]. Phenotypic
changes in the parasite population occurring at later phases of the
infection, such as improved motility, would cause the risk of
progression to vary with post-infection time, but to our knowledge
these have not been observed.
The death rate in stage 2 is another key parameter. Once the
CNS is invaded, poorly understood pathogenic processes such as
macrophage activation and a complex cytokine cascade appear
to be responsible for the onset of neurological symptoms [55].
However, the fact that drugs can halt and partially reverse stage
2 neurological deterioration suggests that this is a cumulative
process due to parasite persistence in the CNS. Stage 2 patients
are known to deteriorate progressively, suggesting that the death
rate would increase with time since onset of stage 2; this time-
dependence would yield a Gompertz distribution of survival in
stage 2 (Figure 2), featuring very little variability in time to
death, and precluding exceptional observations. Greggio [25],
however, described a negative exponential survival of untreated
patients.
Figure 2. Examples of Negative Exponential and Gompertz (Non-Constant Hazard) Distributions of Survival in HAT Stages 1 or 2.
doi:10.1371/journal.pntd.0000303.g002
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Does Human Trypano-Tolerance Exist?
Published data on the natural progression of HAT are
inconclusive. Based on literature and biological considerations,
we believe the following cautious conclusions can be drawn:
1) The majority of untreated gambiense HAT infections
progress to death.
2) There is some evidence that patients can spontaneously
recover from stage 1 HAT infection. However, all such
reports are from West Africa, and may in fact involve strains
other than T. b. gambiense group 1.
3) There is no evidence that chronic carriage exists, although it
is biologically plausible. It is extremely difficult to study this
outcome given current diagnostic sensitivity and the ethical
requirement to treat all detected infections.
4) If spontaneous cure or chronic carriage do occur in stage 1,
they probably constitute a minority of infections.
5) There is no evidence for spontaneous cure from stage 2.
6) Infections either progress to stage 2 within a few years, or
not at all (as suggested by the absence of reports of very long
stage 1 infection in patients who have been away from
HAT-endemic areas for a known period).
7) Durations of infection beyond 6–7 years are extremely rare.
The existence of human trypano-tolerance is difficult to
demonstrate formally, although it may be postulated based on its
occurrence in various animal species. The two methods of
detecting HAT cases, active and passive screening, do not allow
observation of the natural progression of infection, since cases are
treated upon laboratory confirmation, irrespective of symptoms, as
stated above. Similarly, any cases who self-resolve would go
unrecognised. However, it may be possible in selected sites to
identify retrospectively any patients who absconded before
treatment, and verify their status.
Currently, trypanosome classification relies on a rather outdated
isoenzyme profile analysis [56] that may not capture the full
genotypic and phenotypic variability of strains. Better characterisa-
tion of representative samples of strains circulating in various foci
could be attempted using the latest genotyping techniques and
improved methods of trypanosome propagation [57,58]. In the
Ivory Coast, where more modern and specific genotyping
techniques such as PCR on satellite markers have been attempted,
non-gambiense trypanosomes have been shown to infect humans
[29,59,60], suggesting that elsewhere, the range of human-infective
trypanosomes could be more varied than assumed. Geographic
differencesinapparent clinicalseverityofHATinfectionshavebeen
reported for both T. b. gambiense [8,61,62] and T. b. rhodesiense [63],
and may well be due to variations in parasite strain and species.
The use of PCR has also demonstrated low-level trypanosome
infections in a proportion of sero-positive but parasitologically
negative cases [64,65,66]: further study of sero-positive, parasito-
logically negative individuals through PCR or other advanced
techniques is warranted, as this host sub-population could include
chronic carriers with parasite densities below the detection
threshold of currently used field diagnostic tests.
The duration of infectiousness among pathogenic cases is
equally difficult to study. However, some insight about the
distribution of time to symptom onset (a proportion of the total
infectious period) could arise from a review of HAT cases
diagnosed outside Africa over the past decades (we have attempted
to locate all such published reports, but unpublished cases may
exist). Further insight could be gained from asking HAT patients
to recall the time of occurrence of infectious bite chancres
(however, this is an uncommon sign in African patients and may
be a feature of particularly virulent infections).
Implications for Control
The epidemiological implications of the different scenarios
considered for the natural history of HAT infection are outlined in
Table 4. While self-resolving infections would probably be of
limited epidemiological importance, chronic carriers might play a
key role in perpetuating transmission. Indeed, their existence could
explain how certain HAT foci appear to be extinguished, only to
re-awaken mysteriously after several years, or how the chain of
transmission in certain small communities appears to be sustained
by only a handful of cases [67]. Preliminary results from stochastic
modelling (F. Checchi, J. Filipe, D. Chandramohan, unpublished
data) suggest that even a small proportion of chronic carriers
would considerably decrease the chance of repeated active case
detection campaigns detecting a sufficiently large number of
infections to interrupt transmission; more importantly, this chance
would be far lower if, as is plausible, chronic infections were
harder to detect by current diagnostic tools. There is debate about
the relative harms and benefits of treating all serological positives:
in most prevalence scenarios, this results in a positive predictive
value below 30% [68,69], meaning a considerable number of
people are needlessly treated with toxic drugs; however, such a
strategy could detect most trypano-tolerant infections, and might
be warranted as a one-off ‘‘catch-all’’ intervention when
elimination of a focus appears close.
Table 4. Possible Scenarios for Trypano-Tolerance, and Their Likely Implications for Control Strategies
Occurrence of
Trypano-Tolerant
Cases Nature of Trypano-Tolerance
Self-Resolving Infection
Mostly Asymptomatic or Mildly Symptomatic Chronic
Carriage
Frequent Might never be detected through passive screening,
so would need to be detected actively; their contribution to
transmission would depend on their infectiousness and on the
average duration of infection before self-resolution.
Mass screening-based control would be imperative if chronic carriers
have a significant level of infectiousness: its frequency, coverage and
sensitivity would have to be very high to eliminate transmission.
Rare Minimal influence on reproductive ratio, transmission could
perhaps be interrupted through intensive passive screening
even if these cases remain untreated.
Small influence on reproductive ratio, but, if not detected actively,
could be responsible for perpetuating transmission even in settings
with very intensive mass screening-based control.
doi:10.1371/journal.pntd.0000303.t004
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might expect screening to select for strains that permit chronic
carriage, and ultimately for non-pathogenic clones to dominate the
ecology of circulating strains, i.e., transmission would continue but
the disease burden would be reduced. This is probably not borne
out by field observations, as the HAT epidemics resulting from
breakdown of control in the 1970s and 1980s have featured
typically lethal infections. The true ecology of T. b. gambiense strains
is probably far more complex, and regulated by host–vector–
parasite interactions as well as the sharing of genetic material
among strains.
The minority of long-duration pathogenic infections corre-
sponding to the tail of the distribution of natural durations could
also escape control and seed a new epidemic, especially if the end
of a screening programme is decided based on a target prevalence
(e.g., ,0.5%).
If the HAT transmission chain is to be broken, active case
detection with treatment irrespective of symptoms, along with
continued surveillance, remain paramount, regardless of whether
chronic carriers exist [70]. If the existence of a trypano-tolerant
infection reservoir were demonstrated, case detection strategies
could be adapted, for example by introducing systematic
serological treatment (see above) and ensuring very high screening
coverage (based on modelling work previously published by others
[71,72] and currently being done in our group, it is likely that
elimination would not require detecting all chronic carriers). New
safe and easily administered (i.e., oral) drugs would also help to
maximise treatment coverage. Such strategies may maximise the
chances of eliminating the remaining HAT foci. There is currently
a window of opportunity for doing so, as many of the foci are at
their lowest level of activity [73,74] since the start of the post-
colonial period, and there is renewed commitment from the World
Health Organization and other agencies to pursue elimination
[75].
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